Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases

Abstract

Patients classified as BCLC C due to ECOG PS 1 demonstrated longer survival when compared to those presenting with PVT, metastases and/or ECOG PS 2. Hence, ECOG PS 1, as an isolated variable, may not be a true indicator of advanced disease.

Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy

“…Of these, 234 articles were excluded on the basis of their titles and abstract and 54 potentially eligible full-text articles were assessed according to the eligibility criteria. Seventeen studies met the eligibility criteria and were included in the analysis (89101113192021222324293031323334).…”

“…Four studies reported radioembolization data (19202133), ten reported sorafenib data (891011132930313234), and three compared both treatments using a retrospective approach (222324). Among the studies investigating radioembolization, four used glass-based intra-arterial vectors (19202233), two used resin-based vectors (2324), and one used both (21). Six studies were prospective (131929323334), and eleven were retrospective (89101120212223243031).…”

“…Among the studies investigating radioembolization, four used glass-based intra-arterial vectors (19202233), two used resin-based vectors (2324), and one used both (21). Six studies were prospective (131929323334), and eleven were retrospective (89101120212223243031). Sample size ranged from 22 to 269 patients, and the mean patient age ranged from 48 years to 72 years.…”

“…Seven studies were analyzed for the pooled OS analysis of patients treated with radioembolization (19202122232433). The meta-analysis showed that the 3-month, 6-month, and 1-, 2-, and 3-year OS rates were 93% (95% CI, 86–98%; I 2 = 82.4%), 76% (95% CI, 64–85%; I 2 = 83.7%), 47% (95% CI, 38–57%; I 2 = 70.3%), 27% (95% CI, 17–38%; I 2 = 82.5%), and 16% (95% CI, 7–27%; I 2 = 84.8%), respectively (Fig.…”

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience

“…Limitations include the single‐center nature of the analysis without a comparator. Also, survival data in advanced HCC attributed by ECOG 1 may have been overestimated . Strengths include that this represents the largest single‐center prospective cohort of Y90, with sample size and follow‐up permitting meaningful analyses that compensate for heterogeneity of lesion size and liver function.…”